目的 觀察六經(jīng)頭痛片聯(lián)合鹽酸氟桂利嗪治療偏頭痛的臨床效果。方法 選擇2017年1月—2018年11月鄭州煤炭工業(yè)（集團(tuán)）有限責(zé)任公司米村煤礦職工醫(yī)院收治的偏頭痛患者123例，隨機(jī)分為對照組（62例）和治療組（61例）。對照組患者睡前口服鹽酸氟桂利嗪膠囊，2粒/次，1次/d。治療組在對照組用藥基礎(chǔ)上口服六經(jīng)頭痛片，3片/次，3次/d。兩組患者連續(xù)治療3個月。觀察兩組患者臨床療效，同時比較治療前后兩組患者同型半胱氨酸（Hcy）、降鈣素基因相關(guān)肽（CGRP）、5-羥色胺（5-HT）水平，大腦后動脈（PCA）、大腦前動脈（ACA）和大腦中動脈（MCA）血流速度，以及視覺模擬評分法（VAS）評分和頭痛發(fā)作頻率。結(jié)果 治療后，對照組和治療組臨床有效率分別為77.42%和93.44%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者Hcy和CGRP水平顯著降低（P<0.05），而5-HT水平顯著升高（P<0.05）；且治療組患者Hcy、CGRP和5-HT水平改善效果明顯優(yōu)于對照組（P<0.05）。治療后，兩組患者PCA、ACA和MCA血流速度水平，以及VAS評分和頭痛發(fā)作頻率均明顯降低（P<0.05），且治療組患者明顯比對照組低（P<0.05）。結(jié)論 六經(jīng)頭痛片聯(lián)合鹽酸氟桂利嗪治療偏頭痛可降低患者疼痛次數(shù)，降低腦血流速度，安全可靠，具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical effect of Liujing Toutong Tablets combined with flunarizine in treatment of migraine. Methods Patients (123 cases) with migraine in Micun Coal Mine Staff Hospital of Zhengzhou coal industry (Group) Co., Ltd from January 2017 to November 2018 were randomly divided into control (62 cases) and treatment (61 cases) groups. Patients in the control group were po administered with Flunarizine Hydrochloride Capsules before bed, 2 grains/time, once daily. Patients in the treatment group were po administered with Liujing Toutong Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the level of Hcy, CGRP and 5-HT, blood flow velocity of PCA, ACA and MCA, VAS and frequency of headache attack in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 77.42% and 93.44% respectively, and there were differences between two groups (P<0.05). After treatment, the Hcy and CGRP level in two groups was significantly decreased (P<0.05), but the 5-HT level was significantly increased (P<0.05), and the level of Hcy, CGRP and 5-HT in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the blood flow velocity of PCA, ACA and MCA, VAS and frequency of headache attack in two groups were significantly decreased (P<0.05), and these indicators in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Liujing Toutong Tablets combined with flunarizine in treatment of migraine can reduce the frequency of pain and attacks, reduce cerebral blood flow velocity, which is safe and reliable, and has a certain clinical application value.

R971